Last updated on October 2018

A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

Brief description of study

This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks (q4w) for 100 weeks. The primary efficacy assessment will be performed at 105 weeks. The participants who do not enter open-label extension will enter for a long term follow-up period for up to 52 weeks after the last crenezumab dose (Week 153).

Clinical Study Identifier: NCT03114657

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: BN29553 ...

Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre
Heidelberg West, Australia
  Connect »

Reference Study ID Number: BN29553 ...

St Vincent's Hospital Melbourne; Clinical Neuroscience and Neurological Research
Fitzroy, Australia
  Connect »

Reference Study ID Number: BN29553 ...

Royal Melbourne Hospital; Department of Neurology
Parkville, Australia
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.